Tag: heart

MONACO, June 08, 2026 (GLOBE NEWSWIRE) -- With the focus on World Oceans Day, Yacht Club de Monaco has an update on the initiatives it implements throughout the year to support the environmental transition in the yachting sector. Driven by the forward-looking vision of HSH Prince Albert II of Monaco, under the aegis of its ‘Monaco, Capital of Advanced Yachting’ approach, these actions are based on one simple conviction: that the sector’s future depends on concrete, measurable and collective solutions. At the heart of its strategy is the SEA Index^® which has established itself as the benchmark tool for assessing and improving the environmental performance of yachts.

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),² and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6